Arcus Biosciences (RCUS) Payables: 2017-2025
Historic Payables for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $42.0 million.
- Arcus Biosciences' Payables rose 223.08% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.0 million, marking a year-over-year increase of 81.97%. This contributed to the annual value of $18.0 million for FY2024, which is 5.88% up from last year.
- According to the latest figures from Q3 2025, Arcus Biosciences' Payables is $42.0 million, which was up 44.83% from $29.0 million recorded in Q2 2025.
- Arcus Biosciences' 5-year Payables high stood at $42.0 million for Q3 2025, and its period low was $10.0 million during Q4 2021.
- Moreover, its 3-year median value for Payables was $17.0 million (2023), whereas its average is $20.8 million.
- As far as peak fluctuations go, Arcus Biosciences' Payables spiked by 911.71% in 2021, and later plummeted by 45.41% in 2023.
- Arcus Biosciences' Payables (Quarterly) stood at $10.0 million in 2021, then skyrocketed by 100.00% to $20.0 million in 2022, then dropped by 15.00% to $17.0 million in 2023, then increased by 5.88% to $18.0 million in 2024, then skyrocketed by 223.08% to $42.0 million in 2025.
- Its Payables stands at $42.0 million for Q3 2025, versus $29.0 million for Q2 2025 and $22.0 million for Q1 2025.